183 related articles for article (PubMed ID: 37165250)
21. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
[TBL] [Abstract][Full Text] [Related]
22. Eltrombopag, oral immunosuppressant and androgen combination therapy in twelve patients with refractory severe aplastic anemia.
Gao Q; Zhang L; Zhao X; Zhu Y; Peng G; Li Y; Li Y; Li J; Song L; Ye L; Fan H; Zhou K; Yang W; Yang Y; Jing L; Zhang F
Hematology; 2020 Dec; 25(1):341-347. PubMed ID: 32915111
[No Abstract] [Full Text] [Related]
23. Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag.
Li R; Zhou J; Liu Z; Chen X; Long Q; Yang Y; Lin S; Jia J; He G; Li J
Front Immunol; 2022; 13():884312. PubMed ID: 35720405
[TBL] [Abstract][Full Text] [Related]
24. [Efficacy and safety of eltrombopag in aplastic anemia: A multi-center survey in China].
Yang WR; Han B; Chang H; Wu BY; Meng FK; Ji DX; Li YM; Zheng ZJ; Fei Y; Shen JP; Hu P; Ding XQ; Zhang P; Wang YQ; Zhang FK
Zhonghua Xue Ye Xue Za Zhi; 2020 Nov; 41(11):890-895. PubMed ID: 33333690
[No Abstract] [Full Text] [Related]
25. [Successful treatment of eltrombopag following immunosuppressive therapy in pediatric aplastic anemia].
Kubota I; Nagasawa S; Nakagawa M; Yamada A; Kinoshita M; Kamimura S; Shimonodan H; Moritake H
Rinsho Ketsueki; 2023; 64(8):741-745. PubMed ID: 37673625
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis.
Hong Y; Li X; Wan B; Li N; Chen Y
Clin Drug Investig; 2019 Feb; 39(2):141-156. PubMed ID: 30406906
[TBL] [Abstract][Full Text] [Related]
27. Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag.
Cai B; Said Q; Li X; Li FY; Arcona S
J Med Econ; 2020 Mar; 23(3):243-251. PubMed ID: 31686551
[No Abstract] [Full Text] [Related]
28. Upfront Alternative Donor Transplant versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack a Fully HLA-Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies, on Behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation.
Alotaibi H; Aljurf M; de Latour R; Alfayez M; Bacigalupo A; Fakih RE; Schrezenmeier H; Ahmed SO; Gluckman E; Iqbal S; Höchsmann B; Halkes C; de la Fuente J; Alshehry N; Cesaro S; Passweg J; Dufour C; Risitano AM; DiPersio J; Motabi I
Transplant Cell Ther; 2022 Feb; 28(2):105.e1-105.e7. PubMed ID: 34649020
[TBL] [Abstract][Full Text] [Related]
29. Partial SAA patients benefit from delayed response of IST.
Wang T; Wang C; Liu C; Shao Z; Fu R
Front Immunol; 2023; 14():1067977. PubMed ID: 36845107
[TBL] [Abstract][Full Text] [Related]
30. Response To Immunosuppressive Therapy In Patients Of Acquired Aplastic Anaemia: A Single Center Experience From A Developing Country.
Khan M; Iftikhar R; Chaudhry QU; Mehmood SK; Faraz T; Ghafoor T; Shahbaz N; Khan MA; Shamshad GU; Khattak TA
J Ayub Med Coll Abbottabad; 2022; 34(Suppl 1)(4):S969-S973. PubMed ID: 36550655
[TBL] [Abstract][Full Text] [Related]
31. Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag.
Zaimoku Y; Patel BA; Shalhoub R; Groarke EM; Feng X; Wu CO; Young NS
Haematologica; 2022 Jan; 107(1):126-133. PubMed ID: 33910334
[TBL] [Abstract][Full Text] [Related]
32. Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia.
Quintino de Oliveira B; Catto LFB; Santana BAA; Tellechea MF; Scheucher PS; Scheinberg P; Calado RT
Br J Haematol; 2021 Apr; 193(2):410-414. PubMed ID: 33216370
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia.
Goronkova O; Novichkova G; Salimova T; Kalinina I; Baidildina D; Petrova U; Antonova K; Sadovskaya M; Suntsova E; Evseev D; Matveev V; Venyov D; Khachatryan L; Litvinov D; Pshonkin A; Ovsyannikova G; Kotskaya N; Gobadze D; Olshanskaya Y; Popov A; Raykina E; Mironenko O; Voronin K; Purbueva B; Boichenko E; Dinikina Y; Guseynova E; Sherstnev D; Kalinina E; Mezentsev S; Streneva O; Yudina N; Plaksina O; Erega E; Maschan M; Maschan A
Blood Adv; 2023 Mar; 7(6):953-962. PubMed ID: 35446936
[TBL] [Abstract][Full Text] [Related]
34. Immunosuppressive therapy in severe aplastic anemia.
Patel BA; Townsley DM; Scheinberg P
Semin Hematol; 2022 Jan; 59(1):21-29. PubMed ID: 35491055
[TBL] [Abstract][Full Text] [Related]
35. Eltrombopag as frontline treatment of aplastic anaemia in routine practice: implications on cost and efficacy.
Hwang YY; Chan TSY; Chan FHY; Lau CWP; Luk YY; Lau GWN; Chan KP; Leung KH; Kho B; Lau JSM; Lau CK; Mak V; Yip SF; Lin SY; Sim JPY; Kwong YL
Ann Hematol; 2022 Jun; 101(6):1163-1172. PubMed ID: 35412083
[TBL] [Abstract][Full Text] [Related]
36. Comparison of frontline treatment with intensive immunosuppression therapy and HLA-haploidentical hematopoietic stem cell transplantation for young patients with severe aplastic anemia - A meta analysis.
Geng C; Liu X; Chen M; Yang C; Han B
Leuk Res; 2020 Jan; 88():106266. PubMed ID: 31743865
[TBL] [Abstract][Full Text] [Related]
37. Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan.
Imada K; Obara N; Iida H; Imajo K; Maeda T; Usuki K; Fanghong Z; Hombo Y; Tajima T; Kumagai A; Matsuda A; Nakao S
Intern Med; 2021 Apr; 60(8):1159-1168. PubMed ID: 33229810
[TBL] [Abstract][Full Text] [Related]
38. Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy.
Yamazaki H; Ohta K; Iida H; Imada K; Obara N; Tokumine Y; Tomiyama Y; Usuki K; Imajo K; Miyamura K; Sasaki O; Fanghong Z; Hattori T; Tajima T; Matsuda A; Nakao S
Int J Hematol; 2019 Aug; 110(2):187-196. PubMed ID: 31183813
[TBL] [Abstract][Full Text] [Related]
39. Activity of eltrombopag in severe aplastic anemia.
Scheinberg P
Blood Adv; 2018 Nov; 2(21):3054-3062. PubMed ID: 30425070
[TBL] [Abstract][Full Text] [Related]
40. Upfront eltrombopag monotherapy induces stable hematologic remission in pediatric patients with nonsevere idiopathic aplastic anemia.
Geng W; Kearney S; Nelson S
Pediatr Blood Cancer; 2018 Oct; 65(10):e27290. PubMed ID: 29932285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
